6,6-difluoro-1,4-oxazepane hydrochloride | 1341039-23-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧氮杂卓类
• 英文名称: 6,6-difluoro-1,4-oxazepane hydrochloride
• 英文别名: 6,6-Difluoro-1,4-oxazepane hydrochloride；6,6-difluoro-1,4-oxazepane;hydrochloride
• CAS: 1341039-23-3
• 化学式: C₅H₉F₂NO*ClH
• mdl: MFCD21362353
• 分子量: 173.59
• InChiKey: MMOODUDIFAVCIO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.29
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6,6-difluoro-1,4-oxazepane hydrochloride 、 lithium 3-(6,8-difluoroimidazo[1,2-a]pyridin-3-yl)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridine-6-carboxylate 在 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 0.5h， 以54%的产率得到[3-(6,8-difluoroimidazo[1,2-a]pyridin-3-yl)-1-(2,2,2-trifluoroethyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-(6,6-difluoro-1,4-oxazepan-4-yl)methanone
  参考文献：
  名称：

  [EN] 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS
  [FR] DÉRIVÉS DE 5-AZAINDAZOLE UTILISÉS EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE L'ADÉNOSINE

  摘要：

  本发明涉及公式（I）所述的新型5-氮杂吲唑衍生物，以及其药学上可接受的盐、溶剂化合物和前药，以及包含这些化合物的药物组合物。根据本发明的5-氮杂吲唑衍生物已被发现为高效的双重A2A/A2B腺苷受体拮抗剂，因此可以用作治疗剂，特别是用于治疗或预防过度增殖性或传染性疾病或紊乱。

  公开号：

  WO2020083878A1

文献信息

• ERK INHIBITORS
  申请人：Eli Lilly and Company

  公开号：US20160176896A1

  公开（公告）日：2016-06-23

  The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.

  本发明提供了抑制细胞外信号调节激酶（ERK）活性的噻吩[2,3-c]吡咯-4-酮化合物，并可能在癌症治疗中有用。
• HETEROCYLIC COMPOUNDS
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20200247801A1

  公开（公告）日：2020-08-06

  The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

  本发明旨在提供一种具有AMPA受体增强剂作用的杂环化合物，预计可用作预防或治疗抑郁症、阿尔茨海默病、精神分裂症、注意力缺陷多动障碍（ADHD）等疾病的药物。本发明涉及一种由以下式（I）表示的化合物：其中每个符号如说明书所述，或其盐。
• HETEROCYCLIC COMPOUNDS
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP3693360A1

  公开（公告）日：2020-08-12

  The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

  本发明旨在提供一种具有 AMPA 受体增效作用的杂环化合物，该化合物有望用作预防或治疗抑郁症、阿尔茨海默病、精神分裂症、注意缺陷多动障碍（ADHD）等疾病的药物。 本发明涉及一种由式（I）代表的化合物： 其中各符号如说明书所述，或其盐。
• THIENO[2,3-C]PYRROL-4-ONE DERIVATIVES AS ERK INHIBITORS
  申请人：Eli Lilly and Company

  公开号：EP3237423A1

  公开（公告）日：2017-11-01
• 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS
  申请人：Merck Patent GmbH

  公开号：US20210380606A1

  公开（公告）日：2021-12-09

  The present invention relates to novel 5-azaindazole derivatives of formula (I), as described and defined herein, and pharmaceutically acceptable salts, solvates and prodrug thereof, as well as pharmaceutical compositions comprising such compounds. The 5-azaindazole derivatives according to the invention have been found to be highly effective dual A 2A /A 2B adenosine receptor antagonists, and can thus be used as therapeutic agents, particularly in the treatment or prevention of hyperproliferative or infectious diseases or disorders.